New FDA Breakthrough-Drug Category—Implications for Patients (Reply)

In this reply, the authors maintain that the FDA itself acknowledges its expedited-approval programs lower evidentiary thresholds, and that the breakthrough-therapy designation can indirectly weaken standards by generating premature enthusiasm that pressures the agency into approving drugs based on truncated trials and unvalidated biomarkers.